Cargando…

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

OBJECTIVE: Tirzepatide is a novel single-molecule glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, which demonstrated unprecedented improvements in glycemic control and body weight reduction, in the SURPASS phase 3 program. In this exploratory analysis, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenstock, Julio, Vázquez, Luis, Del Prato, Stefano, Franco, Denise Reis, Weerakkody, Govinda, Dai, Biyue, Landó, Laura Fernández, Bergman, Brandon K., Rodríguez, Angel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620542/ https://www.ncbi.nlm.nih.gov/pubmed/37673061 http://dx.doi.org/10.2337/dc23-0872

Ejemplares similares

Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
por: Boye, Kristina S., et al.
Publicado: (2023)

Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
por: Lee, Clare J, et al.
Publicado: (2023)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
por: Lingvay, Ildiko, et al.
Publicado: (2023)

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
por: Viljoen, Adie, et al.
Publicado: (2023)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
por: Sattar, Naveed, et al.
Publicado: (2022)

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
por: Min, Thinzar, et al.
Publicado: (2020)

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
por: Heerspink, Hiddo J.L., et al.
Publicado: (2023)

Aiming at New Targets to Achieve Normoglycemia During Pregnancy
por: Combs, C. Andrew, et al.
Publicado: (2011)

OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2
por: Benneyworth, Brian D, et al.
Publicado: (2022)

THU296 Effect Of Tirzepatide In GADA-positive Individuals With T2D: A Post Hoc Analysis Of The SURPASS 2-5 Trials
por: Peters, Anne L, et al.
Publicado: (2023)

OR03-1 Achievement of HbA1c <6.5% without weight gain and hypoglycemia in people with type 2 diabetes treated with tirzepatide across the phase 3 SURPASS program
por: Allen, Sheryl Elaine, et al.
Publicado: (2022)

Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono substudy)
por: Yabe, Daisuke, et al.
Publicado: (2022)

Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial
por: Ishii, Hitoshi, et al.
Publicado: (2023)

The Burden of Type 2 Diabetes and the Value of Achieving Near Normoglycemia from the Patient Perspective
por: Gelhorn, Heather, et al.
Publicado: (2021)

Nailfold capillaroscopy in diabetes mellitus: a case of neo-angiogenesis after achieving normoglycemia
por: Maldonado, Genessis, et al.
Publicado: (2022)

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes
por: Matza, Louis S., et al.
Publicado: (2022)

Statins surpass SARS
Publicado: (2003)

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
por: Karagiannis, Thomas, et al.
Publicado: (2022)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Big machines surpass themselves
Publicado: (1986)

Les aimants se surpassent
Publicado: (1986)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

Intense Sweetness Surpasses Cocaine Reward
por: Lenoir, Magalie, et al.
Publicado: (2007)

Utility of Fatty Liver Index to predict reversion to normoglycemia in people with prediabetes
por: Busquets-Cortés, Carla, et al.
Publicado: (2021)

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
por: Srinath, Reshmi, et al.
Publicado: (2023)

The Benefits of Safely Achieving Near Normoglycemia from the Perspective of People with Type 2 Diabetes: A Quantitative Survey Study
por: Gelhorn, Heather L, et al.
Publicado: (2022)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
por: Skolnik, Neil, et al.
Publicado: (2021)

LHC surpasses design luminosity with heavy ions
Publicado: (2016)

Surpassing the advanced comes from continuous accumulation
por: Zhang, Baoyuan, et al.
Publicado: (2014)

Surpassing the nonlinear conversion efficiency of soliton microcombs
por: Helgason, Óskar B., et al.
Publicado: (2023)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Clinical and metabolomic predictors of regression to normoglycemia in a population at intermediate cardiometabolic risk
por: Sevilla-González, Magdalena del Rocío, et al.
Publicado: (2021)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_th9str88743i2iqic40p1f7gga